Key information made simple
This summary needs review. Please check the official study record and contact the research team for details.
TerminatedNCT00977522
PF-03463275 for schizophrenia
This study was terminated in the United States. It is testing PF-03463275 for schizophrenia.
SchizophreniaDrugFrom 18 Years to 55 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
Check the study details
Check the official source, then confirm these points with the research team.
View official study record (opens in a new tab)
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateNovember 2009
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 207
- Sponsor
- Pfizer
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT00977522
- Official title
- A Randomized Phase 2, Double-Blind, Placebo-Controlled, Multi-Center Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia Treated With A Stable Dose Of A Second Generation Antipsychotic
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
View official study record (opens in a new tab)The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
United States · 37 sites
- Pfizer Investigational SiteCerritos, CaliforniaSite status: Not listed — confirm with the team
- Pfizer Investigational SiteChula Vista, CaliforniaSite status: Not listed — confirm with the team
- Pfizer Investigational SiteEscondido, CaliforniaSite status: Not listed — confirm with the team
- Pfizer Investigational SiteGarden Grove, CaliforniaSite status: Not listed — confirm with the team
- Pfizer Investigational SiteGlendale, CaliforniaSite status: Not listed — confirm with the team
- Pfizer Investigational SiteLong Beach, CaliforniaSite status: Not listed — confirm with the team
- Pfizer Investigational SiteLong Beach, CaliforniaSite status: Not listed — confirm with the team
- Pfizer Investigational SiteNational City, CaliforniaSite status: Not listed — confirm with the team
- Pfizer Investigational SiteParamount, CaliforniaSite status: Not listed — confirm with the team
- Pfizer Investigational SiteTorrance, CaliforniaSite status: Not listed — confirm with the team
- Pfizer Investigational SiteWashington D.C., District of ColumbiaSite status: Not listed — confirm with the team
- Pfizer Investigational SiteWashington D.C., District of ColumbiaSite status: Not listed — confirm with the team
- Pfizer Investigational SiteAtlanta, GeorgiaSite status: Not listed — confirm with the team
- Pfizer Investigational SiteAtlanta, GeorgiaSite status: Not listed — confirm with the team
- Pfizer Investigational SiteAtlanta, GeorgiaSite status: Not listed — confirm with the team
- Pfizer Investigational SiteDecatur, GeorgiaSite status: Not listed — confirm with the team
- Pfizer Investigational SitePark Ridge, IllinoisSite status: Not listed — confirm with the team
- Pfizer Investigational SiteWichita, KansasSite status: Not listed — confirm with the team
- Pfizer Investigational SiteWichita, KansasSite status: Not listed — confirm with the team
- Pfizer Investigational SiteFlowood, MississippiSite status: Not listed — confirm with the team
- Pfizer Investigational SiteLas Vegas, NevadaSite status: Not listed — confirm with the team
- Pfizer Investigational SiteLas Vegas, NevadaSite status: Not listed — confirm with the team
- Pfizer Investigational SiteRunnemede, New JerseySite status: Not listed — confirm with the team
- Pfizer Investigational SiteToms River, New JerseySite status: Not listed — confirm with the team
- Pfizer Investigational SiteWillingboro, New JerseySite status: Not listed — confirm with the team
- Pfizer Investigational SiteFresh Meadows, New YorkSite status: Not listed — confirm with the team
- Pfizer Investigational SiteHolliswood, New YorkSite status: Not listed — confirm with the team
- Pfizer Investigational SiteStaten Island, New YorkSite status: Not listed — confirm with the team
- Pfizer Investigational SiteStaten Island, New YorkSite status: Not listed — confirm with the team
- Pfizer Investigational SiteEdmond, OklahomaSite status: Not listed — confirm with the team
- Pfizer Investigational SiteOklahoma City, OklahomaSite status: Not listed — confirm with the team
- Pfizer Investigational SitePhiladelphia, PennsylvaniaSite status: Not listed — confirm with the team
- Pfizer Investigational SiteMemphis, TennesseeSite status: Not listed — confirm with the team
- Pfizer Investigational SiteAustin, TexasSite status: Not listed — confirm with the team
- Pfizer Investigational SiteAustin, TexasSite status: Not listed — confirm with the team
- Pfizer Investigational SiteBellaire, TexasSite status: Not listed — confirm with the team
- Pfizer Investigational SiteHouston, TexasSite status: Not listed — confirm with the team
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT00977522. We help you review the study, but cannot decide medical eligibility.
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study involving PF-03463275, Placebo. Phase 2 studies usually explore whether the intervention may work, while continuing to monitor safety.
Who might this study be for?
This study may concern people with schizophrenia; age range: From 18 Years to 55 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
Will I need to change, stop, or stabilize my current treatment?
The public registry appears to mention rules about current treatment, stability, stopping treatment, or dose changes. Do not change your treatment for a study without medical guidance. Ask the study team and your clinician what is required, what is not allowed, and how safety is monitored.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Pfizer, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
TerminatedNCT01568216
20101299: Study Effect of AMG 747 on Schizophrenia Negative Symptoms
This study was terminated in the United States, in Australia, in Canada, .... It focuses on schizophrenia.
TerminatedNCT01568229
20110165: Study Effect of AMG 747 on Schizophrenia Negative Symptoms (Study 165)
This study was terminated in the United States, in France, in the United Kingdom, .... It focuses on schizophrenia.
TerminatedNCT00946985
28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years
This study was terminated in the United States, in Canada, in Brazil, .... It focuses on schizophrenia.